



www.melemapharma.de

MELEMA Pharma GmbH
Rothenbaumchaussee 54
D-20148 Hamburg

is a private clinical stage company and was founded about one and a half years ago and is owned by a group of private investors. Following successful proof of concept in clinical trials, MELEMA will seek partnerships with industry. Revenue from partnership agreements will be invested in further developments.

While legally headquartered of the predominantly virtually company in Hamburg (small administration unit), the scientific base is in Cologne.

MELEMA Pharma is playing in one of the hottest areas in oncology: Immunotherapy.

In principle the immune system is highly effective in destroying cancer cells, however this ability is often suppressed locally and thereby protecting the tumor. Breaking this local tolerance is key to achieving success in cancer immunotherapy.

Our most exciting development candidate ME-503, is in phase II of clinical development. ME-503 is a recombinant lectin which induces strong ribotoxic stress in target cells of the skin. Subcutaneous injection leads to a powerful activation and maturation of dendritic cells – and after migration into the lymph nodes – to a substantial interaction of these cells with cancer fighting T cells. ME-503 has demonstrated efficacy in several phase I, phase I/II and phase II trials. In advanced metastatic melanoma stage IV our compound could improve the overall survival of these patients. After re-evaluation of this phase II trial a patient cohort – 70% of the whole study population - could be defined, where the one year survival rate was 62% and the median overall survival 14.6 months. We are currently planning a larger controlled phase II trial using a powerful biomarker to predict clinical outcome.

Because ME-503 is an immune booster with anticancer efficacy it should be an appropriate agent for combination with other therapeutic drugs such as checkpoint inhibitors.